Delstrigo pill image


doravirine, lamivudine, tenofovir DF DOR (NNRTI), 3TC and TDF (two NRTIs)

Other complete HIV regimen, DHHS recommended initial therapy in certain clinical situations
Single-Tablet Regimen

Standard Dose

One tablet once daily, with or without food, for adults and pediatric patients weighing at least 77 pounds (35 kg) taking HIV treatment for the first time (treatment-naïve) or individuals with suppressed viral load on a stable HIV regimen for at least 6 months who have no known resistance to components of the regimen: doravirine, lamivudine, or tenofovir.

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Dose cannot be adjusted for people with kidney problems; Delstrigo is not recommended for people with estimated creatinine clearance less than 50 mL/min. Should not be used by people with moderate or severe kidney impairment or severe liver impairment.
  • See the individual drugs contained in Delstrigo: Pifeltro, Epivir, and Viread.
  • See package insert for more complete information on potential side effects and interactions.


Merck & Co.
(800) 672-6372



Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments